<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617264</url>
  </required_header>
  <id_info>
    <org_study_id>KaplanMC</org_study_id>
    <nct_id>NCT02617264</nct_id>
  </id_info>
  <brief_title>Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery</brief_title>
  <official_title>Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaplan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess feasibility and clinical utility of marking biopsied axillary lymph nodes with Spot
      at time of biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of the diagnostic tests for breast cancer sometimes necessary to perform a FNA or
      Core biopsy to a suspicious axillary lymph node.

      Presently there is no possibility to identify the examined gland at the surgery. If the gland
      was infected it's most important to remove it.

      The only technique that exists today is marking with a metal clip and the use of this
      technique is not profit, partly because of technical difficulties.

      In this trial the investigator will use a special ink which will be injected to the axillary
      lymph node during the biopsy and latter on the surgery the investigator will try to assess
      the ability to identify the marked gland.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra operative identification the Spot TM marked node at the time of surgery</measure>
    <time_frame>Within 1 year of enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between Spot TM marked lymph node and sentinel lymph node</measure>
    <time_frame>Within 1 year of enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Axillary lymph node FNA Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SPOT</intervention_name>
    <description>Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.</description>
    <arm_group_label>Axillary lymph node FNA Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with findings suspicious of breast cancer (or known breast cancer) who undergo
             axillary lymph node biopsy

        Exclusion Criteria:

          -  Inability to sign Informed Consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanir Allweis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanir Allweis, MD</last_name>
    <email>taniral@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanir Allweis, MD</last_name>
    <phone>+972507874268</phone>
    <email>taniral@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanir M Allweis, MD</last_name>
      <phone>+972-50-7874268</phone>
      <email>taniral@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Luda Levit, B.Sc</last_name>
      <phone>+972-52-6529297</phone>
      <email>ludale@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Tanir M Allweis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaplan Medical Center</investigator_affiliation>
    <investigator_full_name>Tanir M Allweis, MD</investigator_full_name>
    <investigator_title>Head of Department of Breast Health Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

